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Background: AKI frequently develops in sepsis patients, significantly decreasing the overall prognosis. There are
currently no diagnostic markers available which reliably predict the prognosis of sepsis-associated AKI. Recently, ATP
content of CD4+ T cells (ATP_CD4) has been shown to correlate with survival in sepsis. The aim of the study was to
determine ATP_CD4 in sepsis-associated AKI.
Methods: Thirty-three patients with sepsis were prospectively analyzed for ATP_CD4 at three different time points.
Results were related to survival, renal recovery, and further clinical/laboratory findings.
Results: ATP_CD4 tended to lower in concentration at 48 h after onset of sepsis in those patients with complete
renal recovery. There were no differences between patients with no AKI and those with AKI of different severity
(AKIN 1-3). Urinary NGAL did not correlate with renal prognosis.
Conclusion: ATP_CD4 may serve as risk predictor in sepsis-associated AKI. Lower concentrations may indicate a higher
chance of complete renal recovery in sepsis.
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Acute kidney injury (AKI) is still a frequent and serious
complication in hospitalized patients with an incidence
of 5-35% [1]. The most common cause is transient renal
hypoperfusion with tubular cell dysfunction and, in more
severe cases tubular cell apoptosis/necrosis. Therapeutic
measures include elimination of the respective cause,
stabilization of intravascular fluid volume, avoidance of
nephrotoxic drugs, and treatment of secondary compli-
cations such as hyperkalemia and acidosis. Current diag-
nostic markers still do not allow an early diagnosis of
AKI which partly accounts for the poor prognosis of the
disease. In addition, predicting both, renal and general
outcome in AKI remains difficult if not impossible. A
promising candidate is the Neutrophil Gelatinase-
Associated Lipocalin (NGAL) which can being used for* Correspondence: d.patschan@gmail.com
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unless otherwise stated.predicting the need for renal replacement therapy but not
mortality in AKI [2,3]. Lately, the urinary IL-18/creatinine
ratio has been shown to predict persistently elevated serum
creatinine levels of ≥0.3 mg/dl after 6 months as compared
to the baseline [4]. Nevertheless, all available diagnostic pa-
rameters are of limited value since they do not allow moni-
toring of tissue repair processes per se. Postischemic renal
regeneration critically depends on a balanced interaction
between pro- and anti-inflammatory cell populations.
Among those are T and B cell, monocytes/macrophages,
dendritic cells, granulocytes, and plasma cells [5]. How-
ever, a diagnostic method for analyzing activities of cells
involved in renal tissue repair is missing yet. A pilot study
on monitoring activity of CD4+ T cells in sepsis was pub-
lished in 2010. This investigation revealed an association
between low CD4+ ATP (ATP_CD4) content at the time
of ICU admission and poor clinical outcome [6]. Although
such phenomenon is far from being understood mechan-
istically, CD4+ ATP contents most likely reflect activity/
competence of a certain population of immunocompetent
cells. Since AKI is a frequent and deleterious complication
in sepsis, we aimed to investigate ATP_CD4 in septical. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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was to evaluate the prognostic power of ATP_CD4 in
terms of kidney regeneration after sepsis-associated
AKI.Methods
Patients
All patients included in this prospective study were re-
cruited from the intermediate care unit, or the intensive
care unit of the department of Nephrology and Rheumatol-
ogy (University Hospital Göttingen, Germany). The study
protocol was approved after review by the medical local
ethics committee of the University Hospital of Göttingen
(“Klinisches Ethikkomitee der Georg-August-Universität
Göttingen”). It was the only committee which approved
the study since it was a single center analysis. The in-
vestigation conformed to the principles outlined in the
Declaration of Helsinki and written informed consent
was obtained from each subject. Acute kidney injury
was defined using the AKIN criteria [7]. Patients with
pre-existing CKD (chronic kidney disease) were also in-
cluded into the study. In these patients, any further acute
aggravation of renal dysfunction defined AKI if the AKIN
criteria were applicable and/or if, for other reasons, dia-
lysis treatment was initiated. Indications for dialysis
were the presence of two or more of the following cri-
teria: refractory hyperkalemia, increases of serum cre-
atinine >3 mg/dl and/or of blood urea nitrogen >100 mg/dl
at any given time point, and signs/symptoms of fluid over-
load due to diminished urine output, respectively. As in
earlier studies [8,9], sepsis was defined as systemic in-
flammatory response syndrome (SIRS) of infectious ori-
gin [10]. Thus, beside fulfilling the criteria of SIRS [11],
almost all patients showed at least once, positive blood
cultures for either Gram-positive or Gram-negative bac-
teria, and/or clinical symptoms of an infectious disease.
For further clinical characterization a number of different
parameters were documented on a daily basis. All data
analyzed in this study were extracted from a database, be-
longing to the department of Nephrology & Rheumatology
of the University Hospital of Göttingen. All patients were
evaluated clinically and by laboratory findings at the fol-
lowing time points: 24, 48, and 96 hours after inclusion
into the study. Complete renal recovery was defined as
normalization of eGFR, partial renal recovery was defined
as persistent eGFR decline without need for renal replace-
ment therapy. The estimated GFR (eGFR) was calculated
according to the method by Levey and colleagues [12]
(Levey AS, Bosch JP, Lewis JB, et al; A more accurate
method to estimate glomerular filtration rate from serum
creatinine: a new prediction equation. Modification of Diet
in Renal Disease Study Group. Ann Intern Med. 1999 Mar
16;130(6):461-70.).Quantification of ATP in CD4+ T cells
Quantification of ATP in CD4+ T cells was performed
according to a previously published protocol using the
Immuknow assay (Cylex Inc., Columbia, MD, USA) [6].
Quantification of urinary NGAL
Urinary NGAL was measured using the microparticle
immunoassay ‘ARCHITECT Urine NGAL’ (Abbott GmbH
& Co. KG, Wiesbaden) according to the manufacturer’s
protocol.
Statistical analysis
All results are expressed mean ± SD. Differences between
3 or more groups were analyzed by ANOVA. Significance
was considered at p < 0.05. Power analysis was performed
using the programme G*Power®. The test being used was
the f test (IDRE RESEARCH TECHNOLOGY GROUP).
Results
Patients
Patients’ characteristics are summarized in Table 1. A
total of 33 patients were included into the study; 20 male,
13 female. The mean age of all patients was 66 ± 16 years.
Sepsis occurred as a complication of the following dis-
eases: pneumonia [13], urinary tract infection (3), pancrea-
titis (1), cholecystitis (1), and unknown primary infection
[13]. During the course of the disease, 11 patients did not
develop AKI while 22 presented acute renal dysfunction
according to the respective criteria (AKIN 1 8 patients,
AKIN 2 4 patients, AKIN 3 10 patients). Differences
between the four groups were close to the level of sig-
nificance (p = 0.054). The following categories were
significantly different between the four groups: SAPS
at admission (no AKI 28.09 ± 7.89, AKIN 1 38.71 ±
11.21, AKIN 2 42 ± 7.01, AKIN 40.6 ± 11.18, p = 0.016),
positive microbiology (no AKI 4/11, AKIN 1 0/8, AKIN 2
4/4, AKIN 3 6/10, p < 0.01), eGFR at discharge (no
AKI 118 ± 72 ml/min, AKIN 1 39 ± 12 ml/min, AKIN
2 41 ± 19 ml/min, AKIN 3 34 ± 31 ml/min, p < 0.01),
and complete renal recovery (no AKI 11/11, AKIN 1 1/8,
AKIN 2 1/4, AKIN 3 1/10, p < 0.001). All other categories
did not significantly differ between the four groups (Body
Mass Index, maximum SAPS, need for vasopressor ther-
apy, survival, comorbidities such as liver failure, diabetes,
hypertension, preexisting CKD, dialysis dependency at
discharge).
Primary study endpoint: ATP content in CD4+ T cells
Primary study endpoint was ATP content in CD4+ T
cells. This parameter was analyzed in both a longitudinal
(between groups - no AKI, AKIN 1-3) and a horizontal
(comparison at different time points - 24, 48, and 96 h)
manner. Differences between the groups were not signifi-
cant (p = 0.15), those between the three time points were
Table 1 Patients characteristics
Total no AKI AKIN 1 AKIN 2 AKIN 3 p-value
n 33 11 8 4 10
Age 66.15 (±16.42) 60.09 (±16.77) 74 (±12.98) 80.25 (±6.75) 60.9 (±16.79) 0.054 n.s.
Gender
male 20/33 (%) 6/11 5/8 2/4 7/10 0.86
female 13/33 5/11 3/8 2/4 3/10 n.s.
BMI 30.05 (±7.5) 28.43 (±7.89) 31.11 (±9.93) 26.03 (±1.38) 32.36 (±6.57) 0.467 n.s.
SAPS at admission 36.06 (±10.77) 28.09 (±6.89) 38.71 (±11.21) 42 (±7.07) 40.6 (±11.18) 0.016
SAPS max 39.32 (±10.65) 32.73 (±9.45) 42 (±7.75) 43.25 (±6.5) 43.4 (±12.17) 0.077 n.s.
Microbiology positiv 11/33 4/11 0/8 4/4 6/10 <0.01
Vasopressor therapy 11/33 3/11 4/8 0/4 4/10 0.33
Survivor 27/33 11/11 7/8 3/4 6/10 0.11
Comorbidities
liver failure 3/33 0/11 0/8 0/4 3/10 0.085
diabetes mellitus 11/33 2/11 4/8 1/4 5/10 0.39
hypertension 13/33 2/11 5/8 1/4 5/10
CKD 8/33 0/11 3/8 1/4 4/10 0.077
baseline eGFR (ml/min/1.73 m2 73.29 ± 47.01 118.66 ± 27.5 39.73 ± 11.9 40.77 ± 19.37 34.8 ± 31.16 <0.01
Discharge
eGFR 73.29 (±47.01) 118.66 (±27.5) 39.73 (±11.9) 40.77 (±19.37) 34.8 (±31.16) <0.01
death 6/33 0/11 1/8 1/4 4/10
dialysis dependency 1/33 0/11 0/8 0/4 1/10
complete renal recovery 14/33 11/11 1/8 1/4 1/10 <0.001
partial renal recovery 12/33 0/11 6/8 2/4 4/10
For further explanation see text.
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concentrations are summarized in Figure 1. ATP_CD4
was then evaluated in relation to the following parameters:
death, partial renal recovery/dialysis, complete renal re-
covery. Analyses were once again performed in a longi-
tudinal and horizontal manner. Differences were not
statistically significant between any of the three groups
at any of the time points analyzed. However, patients
with complete recovery of renal function tended to
have lower concentrations of ATP_CD4 at 48 hours as
compared to patients with partial recovery or death
(Figure 2). An additional performed power analysis,
using the programme G*Power® showed that a minimum
of 159 patients would have to be included into the study
in order to prove suspected significance (53 individuals
per group - death, partial, complete renal recovery).
Secondary study endpoint: urinary NGAL
Urinary NGAL has been shown to serve as prognostic
marker in AKI [2]. Thus, it is somehow an established
parameter of acute kidney dysfunction. We therefore
measured its concentration in each group/time point,
and also related it to the three categories - death, partialrenal recovery/dialysis, complete renal recovery - in order
to draw more sophisticated conclusions about ATP_CD4.
We identified that urinary NGAL gradually increased with
progressive renal damage in AKI. The lowest values were
measured in patients with no AKI at all (Figure 2). Pa-
tients with AKI and death tended to show higher NGAL
concentrations than patients with complete or partial
renal recovery/dialysis. The latter results were however
not statistically significant. A detailed summary of the
results is given in Figure 2.
Discussion
Our investigation shows that ATP_CD4 may potentially
serve as marker to discriminate between patients with
better post-AKI outcome (complete renal recovery) from
patients with partial recovery of renal function including
persistent need for dialysis, and from patients with
sepsis-associated death. At 48 hours after inclusion into
the study, ATP_CD4 tended to be lower in concentration
in comparison to the two other groups. Nevertheless, dif-
ferences were only close to the level of significance, most
likely as a result of the limited number of subjects. We ex-
trapolated the number of patients necessary for detecting
Figure 1 ATP_CD4 at different time points. Contents did not differ between the four groups and also not between the time points analyzed.
A shows the numerical results, B summarizes dynamics of ATP_CD4 over time (Data as mean ± SD).
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individuals with 53 subjects per individual group would
have to be included into the investigation. Such expanded
study is being initiated at the moment.
Urinary NGAL was useful for differentiating the sever-
ity of acute renal dysfunction. It gradually increased with
progression of AKI from stage 1 to 3 according to the
AKIN criteria. It still remains a fundamental goal to
identify new marker molecules of acute renal damage,
as they are useful for diagnosing AKI at an early stage,
and should also aid with the prediction of both renal and
overall outcome of patients with AKI. Serum creatinine
has been used for more than 50 years now [14]. Although
a number of new promising candidates were identified in
recent years, including Cystatin C [13,15], NGAL [16],
KIM-1 [17], none of them have shown to be superior to
the others in terms of early AKI detection. In addition,
predicting the prognosis of AKI is still very difficult.
This results from the fact that most of the diagnostic
markers available today are eliminated by the kidney, but
do not indicate processes involved in tissue regenerationand repair. Septic AKI significantly results from renal
hypoperfusion causing damage of the tubular epithelium.
Other consequences include intrarenal inflammation and
peritubular microvasculopathy; both significantly modify
dynamics of postischemic tissue regeneration [5]. Never-
theless, indirect methods for monitoring tissue damage
and repair are still lacking. Postischemic intrarenal inflam-
mation is initiated by ischemia-induced release of proin-
flammatory cytokines by tubular epithelial and vascular
endothelial cells, respectively [18]. Increased IL-6 serum
levels have been shown to predict mortality in AKI [19].
In order to monitor activity of T cells in sepsis, a larger
cohort of sepsis patients was analyzed for ATP concen-
trations in the cells (ATP_CD4) [5]. The investigation
showed higher ATP_CD4 in survivors as compared to
non-survivors. Although one may conclude that higher
ATP_CD4 indicate increased cell competence, it is still
not possible to draw any definite conclusions about the
relevance of this finding in the process of self-repair.
Our study, on the other hand, revealed lower ATP_CD4
levels in patients with complete renal recovery after
Figure 2 A - ATP_CD4 related to the three categories complete renal recovery, partial renal recovery/persistent need for dialysis, and
sepsis-associated death. At 48 h, patients with complete renal recovery tended to have lower concentrations of ATP_CD4 compared to the two
other groups. B and C - Urinary NGAL in all patients of the four groups (B) and (C) related to the categories complete renal recovery, partial renal
recovery / persistent need for dialysis, and sepsis-associated death. NGAL gradually increased with increasing severity of AKI (B). Differences were
not significant if related to the prognosis (C) (Data as mean ± SD).
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more recent data about ATP_CD4 in renal transplant
recipients. In this particular study, increased ATP levels
predicted acute renal allograft rejection [20]. Therefore,
lower ATP_CD4 levels may indicate a lower risk for
immune-mediated kidney damage ultimately promoting
faster recovery from sepsis-associated AKI. However, at
this point it is too early to establish ATP_CD4 as new
diagnostic parameter in sepsis-associated AKI or even
to draw definite conclusions about its role in AKI risk
prediction. Further studies must be conducted to con-
firm the promising results of the current investigation.
Particular interest will be related to additional time points
of ATP_CD4 analysis. It needs to be determined whether
ATP_CD4 concentration changes very early, for instance
before sepsis can even be diagnosed. Thus, patients with
increased risk for developing sepsis (e.g. chemotherapy,
other immunosuppressive drugs, diabetes with severe
non-septic infection) will be monitored as well. It should
also be mentioned that the chronic uremic milieu in CKD
may modulate ATP_CD4 in a way that dynamic alter-
ations of ATP content cannot truly be compared with
alterations seen in patients without preexisting CKD.
That aspect would also have to be considered in further
studies. Finally, a more detailed analysis of plasma NGAL
levels is also needed in order to helpidentify patients with
increased risk for CKD after AKI.Conclusion
In conclusion, ATP_CD4 is a promising candidate for
predicting renal prognosis in sepsis-associated AKI. Lower
concentrations at 48 hours after onset of the disease may
indicate a higher chance for complete renal recovery. Fur-
ther investigations are needed, and are underway, in order
to specify its role in AKI risk prediction.
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